These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 21150188

  • 1. Twist and shout: one decade of meta-analyses of erythropoiesis-stimulating agents in cancer patients.
    Bohlius J, Tonia T, Schwarzer G.
    Acta Haematol; 2011; 125(1-2):55-67. PubMed ID: 21150188
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
    Arbuckle RB, Griffith NL, Iacovelli LM, Johnson PE, Jorgenson JA, Kloth DD, Lucarelli CD, Muller RJ.
    Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
    Juneja V, Keegan P, Gootenberg JE, Rothmann MD, Shen YL, Lee KY, Weiss KD, Pazdur R.
    Clin Cancer Res; 2008 Jun 01; 14(11):3242-7. PubMed ID: 18519748
    [Abstract] [Full Text] [Related]

  • 7. Erythropoietin in cancer patients.
    Glaspy JA.
    Annu Rev Med; 2009 Jun 01; 60():181-92. PubMed ID: 18980468
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR, Dunst J, Vaupel P.
    Strahlenther Onkol; 2008 Mar 01; 184(3):121-36. PubMed ID: 18330508
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
    Wauters I, Vansteenkiste J.
    Expert Rev Clin Pharmacol; 2011 Jul 01; 4(4):467-76. PubMed ID: 22114856
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Erythropoietic stimulating agents.
    Testa U.
    Expert Opin Emerg Drugs; 2010 Mar 01; 15(1):119-38. PubMed ID: 20158404
    [Abstract] [Full Text] [Related]

  • 18. Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer.
    Klarenbach S, Manns B, Reiman T, Reaume MN, Lee H, Lloyd A, Wiebe N, Hemmelgarn B, Tonelli M.
    Cancer; 2010 Jul 01; 116(13):3224-32. PubMed ID: 20564645
    [Abstract] [Full Text] [Related]

  • 19. Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma.
    Katodritou E, Dimopoulos MA, Zervas K, Terpos E.
    Cancer Treat Rev; 2009 Dec 01; 35(8):738-43. PubMed ID: 19733008
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.